CA2749537C - Il-1 antagonist compositions for corneal nerve regeneration and protection - Google Patents
Il-1 antagonist compositions for corneal nerve regeneration and protection Download PDFInfo
- Publication number
- CA2749537C CA2749537C CA2749537A CA2749537A CA2749537C CA 2749537 C CA2749537 C CA 2749537C CA 2749537 A CA2749537 A CA 2749537A CA 2749537 A CA2749537 A CA 2749537A CA 2749537 C CA2749537 C CA 2749537C
- Authority
- CA
- Canada
- Prior art keywords
- corneal
- nerve
- loss
- use according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14356109P | 2009-01-09 | 2009-01-09 | |
| US61/143,561 | 2009-01-09 | ||
| PCT/US2010/020646 WO2010081091A2 (en) | 2009-01-09 | 2010-01-11 | Therapeutic compositions for treatment of corneal disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2749537A1 CA2749537A1 (en) | 2010-07-15 |
| CA2749537C true CA2749537C (en) | 2018-11-20 |
Family
ID=42144303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2749537A Expired - Fee Related CA2749537C (en) | 2009-01-09 | 2010-01-11 | Il-1 antagonist compositions for corneal nerve regeneration and protection |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10117906B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2385839B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012515164A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010203425B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2749537C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010081091A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230776T1 (hr) * | 2010-07-29 | 2023-10-27 | Buzzard Pharmaceuticals AB | Himerni antagonisti receptora il-1 tipa i |
| WO2012103240A2 (en) * | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
| WO2013126599A1 (en) | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Meibomian gland dysfunction |
| WO2013126602A1 (en) | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| WO2014036445A2 (en) * | 2012-08-31 | 2014-03-06 | Johnson Michael R | Novel mucolytic agents |
| JP6450364B2 (ja) | 2013-03-13 | 2019-01-09 | セセン バイオ, インコーポレイテッド | 眼送達のためのキメラサイトカイン製剤 |
| SG11201601291QA (en) | 2013-08-23 | 2016-03-30 | Parion Sciences Inc | Dithiol mucolytic agents |
| JP6377618B2 (ja) * | 2013-08-28 | 2018-08-22 | 千寿製薬株式会社 | 角膜上皮障害治療剤 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| BR112017016067A2 (pt) | 2015-01-30 | 2018-04-03 | Parion Sciences Inc | agentes mucolíticos de monotiol |
| JP2018520986A (ja) | 2015-04-30 | 2018-08-02 | パリオン・サイエンシィズ・インコーポレーテッド | ジチオール粘液溶解剤の新規なプロドラッグ |
| US20180312838A1 (en) * | 2015-10-21 | 2018-11-01 | The Regents Of The University Of California | Modulation of microrna 184 to treat pathological lymphangiogenesis |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| WO2020218488A1 (ja) * | 2019-04-26 | 2020-10-29 | 千寿製薬株式会社 | 眼疾患マーカー |
| CN113350326B (zh) * | 2021-07-28 | 2023-03-17 | 爱尔眼科医院集团股份有限公司 | 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用 |
| KR102883890B1 (ko) * | 2021-11-30 | 2025-11-07 | 한림대학교 산학협력단 | miR-30c-1 발현 수준을 증가시키기 위한 제제를 사용하는 각막 내피 세포 배양 방법 및 각막 내피 세포 질환 치료용 조성물 |
| CN118304388B (zh) * | 2024-04-03 | 2025-02-11 | 南通大学 | Tak1在制备治疗周围神经损伤药物中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0610336B1 (en) | 1991-10-31 | 2002-03-27 | The Victoria University Of Manchester | Treatment of neurological conditions by an interleukin-1 inhibiting compound |
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| WO1998022130A1 (en) * | 1996-11-19 | 1998-05-28 | The Schepens Eye Research Institute, Inc. | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| JP3363832B2 (ja) | 1999-05-13 | 2003-01-08 | アルプス電気株式会社 | 薄膜構造体およびその製造方法 |
| US20030104041A1 (en) | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| EP1252895A4 (en) | 2000-01-31 | 2003-04-16 | Santen Pharmaceutical Co Ltd | REMEDIES FOR OPHTHALMIC DISORDERS |
| WO2001057082A2 (en) | 2000-02-03 | 2001-08-09 | Regeneration Technologies, Inc. | Extraction of growth factors from tissue |
| US20010047204A1 (en) * | 2000-03-20 | 2001-11-29 | Medennium, Inc. | Method for determination of a properly sized posterior chamber phakic refractive lens |
| US20020131954A1 (en) | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US20050143333A1 (en) | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| WO2003022213A2 (en) | 2001-09-06 | 2003-03-20 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
| US7683165B2 (en) | 2002-02-20 | 2010-03-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
| US6890654B2 (en) | 2002-04-18 | 2005-05-10 | Northwestern University | Encapsulation of nanotubes via self-assembled nanostructures |
| WO2004060911A2 (en) * | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| US20050033694A1 (en) * | 2003-06-03 | 2005-02-10 | United States Postal Service. | System and method for fleet card management |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| US20050023872A1 (en) * | 2003-07-28 | 2005-02-03 | Hetzel Thomas R. | Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion |
| KR100543466B1 (ko) * | 2003-11-13 | 2006-01-20 | 삼성전자주식회사 | 영상 보간 장치 및 방법 |
| GB0404693D0 (en) | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| US8541413B2 (en) | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| CA2588449A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| JP4815808B2 (ja) | 2005-01-24 | 2011-11-16 | 三菱電機株式会社 | ロータリ圧縮機 |
| CN102293774A (zh) | 2005-03-31 | 2011-12-28 | 旭硝子株式会社 | 前列腺素F2α衍生物的应用 |
| EP1870099A4 (en) | 2005-04-13 | 2008-07-16 | Ube Industries | PROTECTION AGAINST RETINAL NERVOUS CELLS WITH INDAZOLE DERIVATIVE AS ACTIVE SUBSTANCE |
| US7670849B2 (en) | 2005-04-29 | 2010-03-02 | Henkin Robert I | Method for diagnosing insulin resistance from nasal secretions |
| DE602006009834D1 (de) * | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| KR20110079922A (ko) * | 2006-04-14 | 2011-07-11 | 노파르티스 아게 | 안과 장애 치료를 위한 il-1 항체의 용도 |
| US20080026485A1 (en) * | 2006-04-18 | 2008-01-31 | Wolfgang Hueber | Antibody profiling for determination of patient responsiveness |
| CN101489569A (zh) | 2006-06-12 | 2009-07-22 | 席拉坎有限责任公司 | 眼表面疾病的局部治疗 |
| CA2679588A1 (en) * | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
| US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
| EP2187900B1 (en) | 2007-08-16 | 2016-11-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| CA2711696C (en) * | 2008-01-09 | 2021-10-26 | Reza Dana | Therapeutic compositions for treatment of ocular inflammatory disorders |
| US20120014970A1 (en) * | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
| US9011861B2 (en) * | 2010-02-25 | 2015-04-21 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
-
2010
- 2010-01-11 EP EP10700459.0A patent/EP2385839B1/en active Active
- 2010-01-11 CA CA2749537A patent/CA2749537C/en not_active Expired - Fee Related
- 2010-01-11 WO PCT/US2010/020646 patent/WO2010081091A2/en not_active Ceased
- 2010-01-11 US US12/685,510 patent/US10117906B2/en active Active
- 2010-01-11 JP JP2011545490A patent/JP2012515164A/ja active Pending
- 2010-01-11 AU AU2010203425A patent/AU2010203425B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010081091A3 (en) | 2010-11-18 |
| US20100183587A1 (en) | 2010-07-22 |
| AU2010203425A1 (en) | 2011-07-28 |
| CA2749537A1 (en) | 2010-07-15 |
| WO2010081091A2 (en) | 2010-07-15 |
| JP2012515164A (ja) | 2012-07-05 |
| US10117906B2 (en) | 2018-11-06 |
| AU2010203425B2 (en) | 2015-04-09 |
| EP2385839B1 (en) | 2014-11-26 |
| EP2385839A2 (en) | 2011-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010203425B2 (en) | Therapeutic compositions for treatment of corneal disorders | |
| JP5886523B2 (ja) | 眼の炎症性障害を処置するための治療組成物 | |
| US20250195608A1 (en) | Therapeutic Compositions for the Treatment of Dry Eye Disease | |
| EP2187900B1 (en) | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues | |
| JP2011516400A5 (cg-RX-API-DMAC7.html) | ||
| Chucair-Elliott et al. | IL-6 contributes to corneal nerve degeneration after herpes simplex virus type I infection | |
| US20120014970A1 (en) | Therapeutic Compositions for Treatment of Corneal Disorders | |
| US9155790B2 (en) | Methods and compositions for modulating ocular damage | |
| JP6440107B2 (ja) | 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法 | |
| CA2640986C (en) | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues | |
| CN114206849A (zh) | 用于治疗非感染性眼部免疫炎性病症的治疗方法 | |
| WO2017120479A1 (en) | Therapeutics for ocular immunoinflammatory diseases | |
| AU2014227534B2 (en) | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues | |
| 이석재 | Studies on Treatment of Disease Phenotypes of Vision-Threatening Ocular Disease Mouse Models via Intraocular Drugs Delivery | |
| Sabatino et al. | SECTION: Laboratory Science, James V. Jester, PhD, Editor The intriguing role of neuropeptides at the ocular surface |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150105 |
|
| MKLA | Lapsed |
Effective date: 20220111 |